H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Sutro Biopharma to $16 from $20 and keeps a Buy rating on the shares. The analyst says Luvelta’s story "remains in its infancy, with plenty of underappreciated potential." The firm continues to view luvelta "as a best-in-class asset" for PROC patients.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on STRO:
- Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
- Sutro transferred with Equal Weight from Overweight at Wells Fargo
- Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sutro Biopharma appoints Borgman as Chief Medical Officer
- Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer
